Format
Items per page
Sort by

Send to:

Choose Destination

Results: 14

Related Articles by Review for PubMed (Select 21325938)

1.

The role of genotype in 104 cases of diffuse large B-cell lymphoma primary of breast.

Aviles A, Neri N, Nambo MJ.

Am J Clin Oncol. 2012 Apr;35(2):126-9. doi: 10.1097/COC.0b013e318209aa12.

PMID:
21325938
2.

Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma.

Keating GM.

Drugs. 2010 Jul 30;70(11):1445-76. doi: 10.2165/11201110-000000000-00000. Review.

PMID:
20614951
3.

Rituximab (MabThera) for aggressive non-Hodgkin's lymphoma: systematic review and economic evaluation.

Knight C, Hind D, Brewer N, Abbott V.

Health Technol Assess. 2004 Sep;8(37):iii, ix-xi, 1-82. Review.

4.

[Immunologic changes in diffuse large B-cell lymphomas after rituximab-CHOP treatment: own data and review of the literature].

Simon Z, Illés A, Miltényi Z, Magyari F, Váróczy L, Péter N, Gergely L.

Orv Hetil. 2012 Oct 21;153(42):1658-66. doi: 10.1556/OH.2012.29471. Review. Hungarian.

PMID:
23063898
5.

Maintenance therapy in diffuse large B-cell lymphoma.

Michallet AS, Lebras L, Coiffier B.

Curr Opin Oncol. 2012 Sep;24(5):461-5. doi: 10.1097/CCO.0b013e3283562036. Review.

PMID:
22759738
6.

Moving beyond rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone for diffuse large B-cell lymphoma.

Roschewski M, Dunleavy K, Wilson WH.

Leuk Lymphoma. 2014 Nov;55(11):2428-37. doi: 10.3109/10428194.2014.883075. Epub 2014 Mar 7. Review.

PMID:
24438195
7.

Primary diffuse large B-cell lymphoma of the breast: looking at pathogenesis, clinical issues and therapeutic options.

Aviv A, Tadmor T, Polliack A.

Ann Oncol. 2013 Sep;24(9):2236-44. doi: 10.1093/annonc/mdt192. Epub 2013 May 26. Review.

8.

New insights into the biology of molecular subtypes of diffuse large B-cell lymphoma and Burkitt lymphoma.

Frick M, Dörken B, Lenz G.

Best Pract Res Clin Haematol. 2012 Mar;25(1):3-12. doi: 10.1016/j.beha.2012.01.003. Epub 2012 Feb 8. Review.

PMID:
22409819
9.

Diffuse large B cell lymphoma: how can we cure more patients in 2012?

Moskowitz C.

Best Pract Res Clin Haematol. 2012 Mar;25(1):41-7. doi: 10.1016/j.beha.2012.01.008. Epub 2012 Feb 24. Review.

PMID:
22409822
10.

Diffuse large B-cell non-Hodgkin lymphoma in the very elderly: challenges and solutions.

Latta S, Cygan PH, Fried W, Nabhan C.

Oncology (Williston Park). 2013 Feb;27(2):126-30, 132-6, 138. Review.

11.

Relapses, treatments and new drugs.

Mounier N, Gisselbrecht C.

Best Pract Res Clin Haematol. 2012 Mar;25(1):49-60. doi: 10.1016/j.beha.2012.01.002. Epub 2012 Feb 4. Review.

PMID:
22409823
12.

C-MYC aberrations as prognostic factors in diffuse large B-cell lymphoma: a meta-analysis of epidemiological studies.

Zhou K, Xu D, Cao Y, Wang J, Yang Y, Huang M.

PLoS One. 2014 Apr 16;9(4):e95020. doi: 10.1371/journal.pone.0095020. eCollection 2014. Review.

13.

Tandem triplication of the BCL2 gene in CD5-positive intravascular large B cell lymphoma with bone marrow involvement.

Yamamoto K, Okamura A, Yakushijin K, Hayashi Y, Matsuoka H, Minami H.

Ann Hematol. 2014 Oct;93(10):1791-3. doi: 10.1007/s00277-014-2035-y. Epub 2014 Feb 28. Review. No abstract available.

PMID:
24577512
14.

[Primary bone marrow diffuse large B cell lymphoma: three case reports and literature review].

Liu H, Yi S, Liu E, Li Z, Zhang H, Ru K, Zou D, Qiu L.

Zhonghua Xue Ye Xue Za Zhi. 2014 Oct;35(10):914-7. doi: 10.3760/cma.j.issn.0253-2727.2014.10.009. Review. Chinese.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk